Detalhe da pesquisa
1.
Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.
Lancet Oncol
; 13(7): 696-706, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22652183
2.
Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
Clin Infect Dis
; 41(8): 1186-95, 2005 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16163639
3.
Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma.
Leuk Lymphoma
; 52(4): 620-8, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21438830
4.
Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
J Infect Dis
; 189(1): 51-60, 2004 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14702153
5.
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.
J Infect Dis
; 190(2): 280-4, 2004 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15216462